<DOC>
	<DOCNO>NCT01648179</DOCNO>
	<brief_summary>This study open-label , randomize , single dose , four period , balance crossover study ass eligible healthy male female subject .</brief_summary>
	<brief_title>A Study Assess Relative Bioavailability Three Formulations Food Effect GSK1322322 Healthy Subjects</brief_title>
	<detailed_description>This study open-label , randomize , single dose , four period , balance crossover study ass eligible healthy male female subject : - The relative bioavailability wet mill GSK1322322 tablet formulation without food compare oral mesylate salt solution . - The effect body weight pharmacokinetics GSK1322322 give either orally IV . - The absolute bioavailability wet mill tablet oral mesylate salt solution compare IV formulation .</detailed_description>
	<mesh_term>Bacterial Infections</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<criteria>ALT , alkaline phosphatase bilirubin ≤ 1.5xULN ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . QTcB &lt; 450 msec ; QTcB &lt; 480 msec subject Bundle Branch Block . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test cardiac monitoring . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK Medical Monitor agree find unlikely introduce additional risk factor interfere study procedure . Male female ( non childbearing potential ) 18 65 year age inclusive , time signing informed consent . A female subject eligible participate : Nonchildbearing potential define premenopausal female document tubal ligation hysterectomy ; postmenopausal define 12 month spontaneous amenorrhea [ questionable case blood sample withsimultaneous follicle stimulate hormone ( FSH ) &gt; 40 MlU/ml estradiol &lt; 40 pg/ml ( &lt; 147 pmol/L ) confirmatory ] . Male subject female partner childbearing potential must agree use one contraception method list Section 8.1 . This criterion must follow time first dose study medication final follow visit . Body weight ≥ 40 kg ( Refer Table 3 weight stratification detail ) . Capable give write informed consent , include compliance requirement restriction list consent form . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) . A positive prestudy drug/alcohol screen . A positive test HIV antibody . History regular alcohol consumption within 6 month study define : An average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 ml ) beer , 5 ounce ( 150 ml ) wine 1.5 ounce ( 45 ml ) 80 proof distil spirit . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) . Exposure four new chemical entity within 12 month prior first dose day . Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety due potential drug interaction . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation.10 . Where participation study would result donation blood blood product excess 500 mL within 56 day period . Pregnant female determine positive [ serum urine ] hCG test screen prior dosing . Lactating female . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . History sensitivity heparin heparininduced thrombocytopenia . Urinary cotinine level indicative smoke history regular use tobacco nicotinecontaining product within 6 month prior screen . Unable refrain consumption red wine , seville orange , grapefruit grapefruit juice [ and/or pummelo , exotic citrus fruit , grapefruit hybrid fruit juice ] 7 day prior first dose study medication . Exclusion criterion screen ECG ( single repeat allow eligibility determination ) : Males Females Heart rate &lt; 45 &gt; 100 bpm &lt; 50 &gt; 100 bpm PR Interval &lt; 120 &gt; 220 msec QRS duration &lt; 70 &gt; 120 msec QTc interval ( Bazett ) &gt; 450 msec Evidence previous myocardial infarction ( include ST segment change associate repolarization ) . Any conduction abnormality ( include specific leave right complete bundle branch block , AV block [ 2nd degree high ] , Wolf Parkinson White [ WPW ] syndrome ) , sinus pause &gt; 3 second , nonsustained sustain ventricular tachycardia ( ≥3 consecutive ventricular ectopic beat ) significant arrhythmia , opinion principal investigator GSK medical monitor , interfere safety individual subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>GSK1322322 , relative bioavailability , healthy subject , open label , food effect , weight effect</keyword>
</DOC>